{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:07:13Z","timestamp":1788937633364,"version":"build-2803163510"},"reference-count":139,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic urticaria is a mast cell\u2013driven inflammatory disease characterized by recurrent wheals, angioedema or both for more than 6\u2009weeks, with substantial effects on sleep, quality of life, mental health and daily functioning. Type I autoallergic and type IIb autoimmune mechanisms represent major endotypes, but many patients show overlapping or mixed features, contributing to heterogeneous clinical courses and variable treatment responses. Current management relies on confirming the diagnosis, excluding differential diagnoses, identifying aggravating factors and comorbidities and monitoring disease activity and control using validated patient\u2010reported outcome measures. A limited, clinically guided diagnostic workup is preferred, with extended investigations reserved for selected cases based on history, examination, red flags or isolated angioedema. Second\u2010generation H1\u2010antihistamines remain the first\u2010line therapy, with up\u2010dosing recommended in insufficient responders. Omalizumab has transformed the treatment of antihistamine\u2010refractory disease, while newer options such as dupilumab and remibrutinib further expand the therapeutic landscape. Ciclosporin remains an effective option in selected patients, particularly those with severe or difficult\u2010to\u2010treat disease, but requires careful safety monitoring. In chronic inducible urticaria, provocation testing, threshold assessment, trigger counselling and individualized treatment are central to care. Despite recent advances, important unmet needs remain, including reliable biomarkers for endotyping, evidence\u2010based selection among emerging therapies, better data in children and other special populations, standardized definitions of remission and relapse and disease\u2010modifying strategies. Future management is expected to move towards biomarker\u2010driven, personalized care, enabling more precise treatment selection and sustained disease control.<\/jats:p>","DOI":"10.1111\/jdv.70637","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:45:02Z","timestamp":1788936302000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of chronic urticaria: Current status and future prospect"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-926X","authenticated-orcid":false,"given":"Anda\u00e7","family":"Salman","sequence":"first","affiliation":[{"name":"Department of Dermatology Acibadem University School of Medicine  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-5363","authenticated-orcid":false,"given":"Mona","family":"Al\u2010Ahmad","sequence":"additional","affiliation":[{"name":"Department of Microbiology, College of Medicine University of Kuwait  Kuwait Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-0214","authenticated-orcid":false,"given":"Maryam","family":"Al\u2010Nesf","sequence":"additional","affiliation":[{"name":"Adult Allergy and Immunology Division Hamad Medical Corporation  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-3279","authenticated-orcid":false,"given":"Chia\u2010Yu","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Dermatology National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-3619","authenticated-orcid":false,"given":"Luis Felipe","family":"Ensina","sequence":"additional","affiliation":[{"name":"Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics Federal University of S\u00e3o Paulo  S\u00e3o Paulo Brazil"},{"name":"Hospital S\u00edrio\u2010Liban\u00eas  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-7753","authenticated-orcid":false,"given":"Ana M.","family":"Gimenez\u2010Arnau","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute Universitat Pompeu Fabra  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-1360","authenticated-orcid":false,"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital, Unidade Local de Sa\u00fade de Coimbra  Coimbra Portugal"},{"name":"Faculty of Medicine University of Coimbra  Coimbra Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8466-4351","authenticated-orcid":false,"given":"Clive","family":"Grattan","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology Guy's Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-6034","authenticated-orcid":false,"given":"Michihiro","family":"Hide","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hiroshima City Hiroshima Citizens Hospital  Hiroshima Japan"},{"name":"Department of Dermatology, Graduate School of Biomedical and Health Sciences Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5380-8132","authenticated-orcid":false,"given":"Pavel","family":"Kolkhir","sequence":"additional","affiliation":[{"name":"Institute of Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-9976","authenticated-orcid":false,"given":"Martin","family":"Metz","sequence":"additional","affiliation":[{"name":"Institute of Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0346-9675","authenticated-orcid":false,"given":"Iman","family":"Nasr","sequence":"additional","affiliation":[{"name":"Clinical Immunology and Allergy Unit Royal Hospital  Muscat Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-2742","authenticated-orcid":false,"given":"Romi","family":"Saini","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology Johns Hopkins University School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-300X","authenticated-orcid":false,"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Department of Dermatology Bispebjerg Hospital, University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-8875","authenticated-orcid":false,"given":"Torsten","family":"Zuberbier","sequence":"additional","affiliation":[{"name":"Institute of Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-0959","authenticated-orcid":false,"given":"Emek","family":"Kocaturk","sequence":"additional","affiliation":[{"name":"Institute of Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"},{"name":"Department of Dermatology, School of Medicine Bahcesehir University  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"e_1_2_19_2_1","doi-asserted-by":"crossref","unstructured":"Kocat\u00fcrkE GrattanC CherrezI ChoYT DeA DemirS et\u00a0al.The overall burden of chronic spontaneous urticaria \u2013 the current landscape.Br J Dermatol2026.","DOI":"10.1093\/bjd\/ljag121"},{"issue":"2","key":"e_1_2_19_3_1","first-page":"107","article-title":"Clinical phenotypes and molecular endotypes of chronic urticaria: linking clinical expression to underlying immune mechanisms","volume":"16","author":"T\u00fcrk M","year":"2026","journal-title":"Asia Pac Allergy"},{"issue":"10","key":"e_1_2_19_4_1","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/jdv.20772","article-title":"Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries","volume":"39","author":"Balp MM","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"e_1_2_19_5_1","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/all.15287","article-title":"Prevalence and risk factors of chronic urticaria in China: a nationwide cross\u2010sectional study","volume":"77","author":"Zhang X","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"e_1_2_19_6_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta\u2010analysis","volume":"75","author":"Fricke J","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"e_1_2_19_7_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jdv.70027","article-title":"Sex matters in CSU: women face greater burden and poorer urticaria control, especially in midlife\u2010CURE insights","volume":"40","author":"Kocat\u00fcrk E","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_19_8_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13555-021-00641-6","article-title":"Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review","volume":"12","author":"Balp MM","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_19_9_1","unstructured":"ZuberbierT Abdul Hameed AnsariZ Abdul LatiffAH AbuzakoukMM Agcaoili\u2010De JesusMS AgondiRC et\u00a0al.The international guideline for the definition classification diagnosis and management of urticaria.Allergy2026."},{"issue":"3","key":"e_1_2_19_10_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alit.2023.05.003","article-title":"Chronic urticaria and the pathogenic role of mast cells","volume":"72","author":"Elieh\u2010Ali\u2010Komi D","year":"2023","journal-title":"Allergol Int"},{"key":"e_1_2_19_11_1","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.jaip.2023.02.022","article-title":"Chronic spontaneous urticaria: the role and relevance of autoreactivity, autoimmunity, and autoallergy","volume":"11","author":"Asero R","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"e_1_2_19_12_1","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not viceversa","volume":"11","author":"Xiang YK","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"e_1_2_19_13_1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/ACI.0000000000000927","article-title":"Chronic spontaneous urticaria: new evidences on the role of autoimmunity","volume":"23","author":"Xiang YK","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"e_1_2_19_14_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11882-025-01215-8","article-title":"Autoallergy and what the allergist needs to know","volume":"25","author":"Steinert C","year":"2025","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"e_1_2_19_15_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4168\/aair.2019.11.1.29","article-title":"Causal relationship between anti\u2010TPO IgE and chronic urticaria by in\u00a0vitro and in\u00a0vivo tests","volume":"11","author":"S\u00e1nchez J","year":"2019","journal-title":"Allergy, Asthma Immunol Res"},{"issue":"3","key":"e_1_2_19_16_1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2017.10.035","article-title":"IL\u201024 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria","volume":"142","author":"Schmetzer O","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"e_1_2_19_17_1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/all.13587","article-title":"Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria","volume":"73","author":"Cugno M","year":"2018","journal-title":"Allergy"},{"issue":"2","key":"e_1_2_19_18_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000350388","article-title":"Significantly high levels of anti\u2010dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients","volume":"161","author":"Kashiwakura JI","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"issue":"9","key":"e_1_2_19_19_1","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1111\/all.15734","article-title":"One in five patients with chronic spontaneous urticaria has IgE to tissue transglutaminase 2","volume":"78","author":"Su H","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"e_1_2_19_20_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2025.10.025","article-title":"Understanding IgE\u2010mediated autoimmunity and autoallergy","volume":"157","author":"Mo\u00f1ino\u2010Romero S","year":"2026","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"e_1_2_19_21_1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir P","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"e_1_2_19_22_1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study","volume":"74","author":"Schoepke N","year":"2019","journal-title":"Allergy"},{"issue":"5","key":"e_1_2_19_23_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling\u2010a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein JA","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"e_1_2_19_24_1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.20249","article-title":"Beyond the classic players: mas\u2010related G protein\u2010coupled receptor member X2 role in pruritus and skin diseases","volume":"39","author":"Kumar M","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_19_25_1","article-title":"Peptides of major basic protein and eosinophil cationic protein activate human mast cells","volume":"21","author":"Ogasawara H","year":"2019","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"e_1_2_19_26_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas\u2010related G protein\u2010coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"K\u00fchn H","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"e_1_2_19_27_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","article-title":"Expression of mas\u2010related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa D","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"e_1_2_19_28_1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4168\/aair.2021.13.3.498","article-title":"Elevated MRGPRX2 levels related to disease severity in patients with chronic spontaneous urticaria","volume":"13","author":"Cao TBT","year":"2021","journal-title":"Allergy, Asthma Immunol Res"},{"issue":"1","key":"e_1_2_19_29_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2025.03.007","article-title":"MRGPRX2 gain\u2010of\u2010function mutation drives enhanced mast cell reactivity in chronic spontaneous urticaria","volume":"156","author":"Ye D","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"e_1_2_19_30_1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jaci.2005.12.1343","article-title":"Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal\u2010and\u2010flare reactions much more frequently than autologous serum","volume":"117","author":"Asero R","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"e_1_2_19_31_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1398-9995.2007.01514.x","article-title":"Severe chronic urticaria is associated with elevated plasma levels of D\u2010dimer","volume":"63","author":"Asero R","year":"2008","journal-title":"Allergy"},{"issue":"5","key":"e_1_2_19_32_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1398-9995.2009.02222.x","article-title":"Coagulation\/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria","volume":"65","author":"Takahagi S","year":"2010","journal-title":"Allergy"},{"issue":"2","key":"e_1_2_19_33_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000155748","article-title":"Expression of tissue factor by eosinophils in patients with chronic urticaria","volume":"148","author":"Cugno M","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"e_1_2_19_34_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/all.14110","article-title":"Increase of tissue factor expression on the surface of peripheral monocytes of patients with chronic spontaneous urticaria","volume":"75","author":"Saito R","year":"2020","journal-title":"Allergy"},{"issue":"2","key":"e_1_2_19_35_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-2999(03)01752-7","article-title":"Activation of mast cells induced by agonists of proteinase\u2010activated receptors under normal conditions and during acute inflammation in rats","volume":"471","author":"Dugina TN","year":"2003","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"e_1_2_19_36_1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jaci.2020.08.018","article-title":"Coagulation factors induce human skin mast cell and basophil degranulation via activation of complement 5 and the C5a receptor","volume":"147","author":"Yanase Y","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"e_1_2_19_37_1","first-page":"43","article-title":"Activation of coagulation, anti\u2010coagulation, fibrinolysis and the complement system in patients with urticaria","volume":"31","author":"Zhu H","year":"2013","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"e_1_2_19_38_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1067\/mai.2002.120954","article-title":"A role for C5a in augmenting IgG\u2010dependent histamine release from basophils in chronic urticaria","volume":"109","author":"Kikuchi Y","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"e_1_2_19_39_1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.jaip.2021.03.033","article-title":"The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells","volume":"9","author":"Gim\u00e9nez\u2010Arnau AM","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_2_19_40_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1327040","article-title":"CD4+CCR5+ T cells and CCL3+ mast cells are increased in the skin of patients with chronic spontaneous urticaria","volume":"15","author":"Mubariki R","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_19_41_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-017-0197-6","article-title":"The relationship between circulating concentrations of interleukin 17 and C reactive protein in chronic spontaneous urticaria","volume":"13","author":"Grzanka A","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"e_1_2_19_42_1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1365-2222.2011.03789.x","article-title":"Plasma IL\u20106 concentration correlates with clinical disease activity and serum C\u2010reactive protein concentration in chronic urticaria patients","volume":"41","author":"Kasperska\u2010Zajac A","year":"2011","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"e_1_2_19_43_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.cyto.2013.01.015","article-title":"Free IL\u201018 and IL\u201033 cytokines in chronic spontaneous urticaria","volume":"61","author":"Puxeddu I","year":"2013","journal-title":"Cytokine"},{"issue":"6","key":"e_1_2_19_44_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00403-024-02966-6","article-title":"Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria","volume":"316","author":"Ho\u015fg\u00f6ren\u2010Tekin S","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"e_1_2_19_45_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/ds.DS-D-24-00136","article-title":"Evaluation of the effect of adding probiotic supplementation in patients with chronic spontaneous urticaria","volume":"42","author":"Can PK","year":"2024","journal-title":"Dermatol Sin"},{"issue":"1","key":"e_1_2_19_46_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41467-023-44373-x","article-title":"Gut microbiota facilitate chronic spontaneous urticaria","volume":"15","author":"Zhu L","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"e_1_2_19_47_1","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1111\/all.14412","article-title":"IgM and IgA in addition to IgG autoantibodies against Fc\u025bRI\u03b1 are frequent and associated with disease markers of chronic spontaneous urticaria","volume":"75","author":"Altrichter S","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"e_1_2_19_48_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer M","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"e_1_2_19_49_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke J","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"e_1_2_19_50_1","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","article-title":"Association between serum Total IgE levels and clinical response to Omalizumab for chronic spontaneous urticaria: a systematic review and meta\u2010analysis","volume":"11","author":"Chuang KW","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"e_1_2_19_51_1","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.jaip.2021.07.043","article-title":"Autoimmune chronic spontaneous urticaria detection with IgG anti\u2010TPO and Total IgE","volume":"9","author":"Kolkhir P","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"e_1_2_19_52_1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jaip.2022.02.039","article-title":"Is anti\u2010TPO IgG and total IgE clinically useful for the detection of autoimmune chronic spontaneous urticaria?","volume":"10","author":"Sanchez J","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_2_19_53_1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaip.2026.03.033","article-title":"Clinical evolution of acute urticaria and association with IgE autoantibodies","volume":"14","author":"S\u00e1nchez J","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"e_1_2_19_54_1","doi-asserted-by":"crossref","DOI":"10.1007\/s40521-026-00415-5","article-title":"Paraclinics in chronic spontaneous urticaria: are they useful as biomarkers?","volume":"13","author":"Y\u00fccel MB","year":"2026","journal-title":"Curr Treat Options Allergy"},{"issue":"4","key":"e_1_2_19_55_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.anai.2024.10.026","article-title":"Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine","volume":"134","author":"Lang DM","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"e_1_2_19_56_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaci.2025.04.004","article-title":"Endotypes of chronic spontaneous urticaria and angioedema","volume":"156","author":"Wong D","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"e_1_2_19_57_1","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok JS","year":"2021","journal-title":"Allergy"},{"issue":"11","key":"e_1_2_19_58_1","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.jaip.2023.08.020","article-title":"Patients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment\u2010results from CURE","volume":"11","author":"Buttgereit T","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"e_1_2_19_59_1","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.jaip.2025.07.021","article-title":"Management of chronic spontaneous urticaria made practical: what every clinician should know","volume":"13","author":"Kocat\u00fcrk E","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"e_1_2_19_60_1","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.jaip.2025.07.008","article-title":"Clinical evaluation and outcome measures of chronic spontaneous urticaria and chronic inducible urticaria","volume":"13","author":"Weller K","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"e_1_2_19_61_1","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12328","article-title":"CRUSE\u00ae \u2013 an innovative mobile application for patient monitoring and management in chronic spontaneous urticaria","volume":"14","author":"Neisinger S","year":"2024","journal-title":"Clin Transl Allergy"},{"issue":"17","key":"e_1_2_19_62_1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: a review","volume":"332","author":"Kolkhir P","year":"2024","journal-title":"JAMA"},{"issue":"10450","key":"e_1_2_19_63_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","article-title":"Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment","volume":"404","author":"Zuberbier T","year":"2024","journal-title":"Lancet"},{"key":"e_1_2_19_64_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109198","article-title":"An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria","volume":"112","author":"Ayse Ornek S","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"e_1_2_19_65_1","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13925","article-title":"Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: clinical features, associated conditions and indicators of treatment response","volume":"34","author":"\u00d6z\u00e7eker D","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"issue":"12","key":"e_1_2_19_66_1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/jamadermatol.2025.3663","article-title":"Patient values and preferences in chronic urticaria treatment: a systematic review","volume":"161","author":"Chu X","year":"2025","journal-title":"JAMA Dermatol"},{"key":"e_1_2_19_67_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1584771","article-title":"Chronic inducible urticaria \u2010 having more than one is common and clinically relevant","volume":"16","author":"Lebedkina M","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"e_1_2_19_68_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jdv.19637","article-title":"A comparative analysis of chronic inducible urticaria in 423 patients: clinical and laboratory features and comorbid conditions","volume":"38","author":"Ornek Ozdemir S","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"e_1_2_19_69_1","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1159\/000536579","article-title":"Unveiling treatment response predictors in predominant subtypes of chronic inducible urticaria","volume":"185","author":"Ozdemir SO","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"e_1_2_19_70_1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing, and management of chronic inducible urticarias \u2010 the EAACI\/GA2LEN\/EDF\/UNEV consensus recommendations 2016 update and revision","volume":"71","author":"Magerl M","year":"2016","journal-title":"Allergy"},{"issue":"12","key":"e_1_2_19_71_1","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/all.13878","article-title":"Diagnosis and treatment of chronic inducible urticaria","volume":"74","author":"Maurer M","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"e_1_2_19_72_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.02.283","article-title":"Management of chronic inducible urticaria according to the guidelines: a prospective controlled study","volume":"87","author":"Kocat\u00fcrk E","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"1","key":"e_1_2_19_73_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/bjd.19425","article-title":"Omalizumab for the treatment of chronic inducible urticaria in 80 patients","volume":"184","author":"Exposito\u2010Serrano V","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"e_1_2_19_74_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer M","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"e_1_2_19_75_1","first-page":"e679","article-title":"Effectiveness of Omalizumab in patients with chronic inducible urticaria: real\u2010life experience from two UCARE centres","volume":"35","author":"Can PK","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"e_1_2_19_76_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/all.16334","article-title":"Omalizumab is effective and safe in chronic inducible urticaria (CIndU): real\u2010world data from a large multi\u2010national UCARE study","volume":"80","author":"Soegiharto R","year":"2025","journal-title":"Allergy"},{"issue":"5","key":"e_1_2_19_77_1","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.jaci.2018.01.031","article-title":"Chronic inducible urticaria: a systematic review of treatment options","volume":"141","author":"Dressler C","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"e_1_2_19_78_1","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/all.15194","article-title":"Risk factors for systemic reactions in typical cold urticaria: results from the COLD\u2010CE study","volume":"77","author":"Bizjak M","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"e_1_2_19_79_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hup.1184","article-title":"Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography: comparison of H1 receptor occupancy and proportional impairment ratio","volume":"26","author":"Kubo N","year":"2011","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"e_1_2_19_80_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/all.15854","article-title":"Efficacy and safety of on\u2010demand versus daily rupatadine in chronic spontaneous urticaria: a randomized trial","volume":"79","author":"Weller K","year":"2024","journal-title":"Allergy"},{"issue":"8","key":"e_1_2_19_81_1","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.jaip.2024.05.011","article-title":"Evaluation of guideline line\u2010care approach to the treatment of chronic inducible urticaria","volume":"12","author":"S\u00e1nchez J","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"e_1_2_19_82_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaip.2017.06.002","article-title":"Evaluation of a guidelines\u2010based approach to the treatment of chronic spontaneous urticaria","volume":"6","author":"S\u00e1nchez J","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"e_1_2_19_83_1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/0190-9622(91)70163-V","article-title":"Therapeutic effects of cetirizine in delayed pressure urticaria: Clinicopathologic findings","volume":"24","author":"Kontou\u2010Fili K","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"e_1_2_19_84_1","first-page":"324","article-title":"Double\u2010blind crossover study of high\u2010dose cetirizine in cholinergic urticaria","volume":"193","author":"Zuberbier T","year":"1996","journal-title":"Dermatology"},{"issue":"3","key":"e_1_2_19_85_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult\u2010to\u2010treat urticaria","volume":"125","author":"Staevska M","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"e_1_2_19_86_1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaci.2008.12.008","article-title":"High\u2010dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard\u2010dose treatment in patients with acquired cold urticaria: a randomized, placebo\u2010controlled, crossover study","volume":"123","author":"Siebenhaar F","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"e_1_2_19_87_1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1468-3083.2009.03289.x","article-title":"The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo\u2010controlled treatment with rupatadine 10 and 20 mg","volume":"23","author":"Gim\u00e9nez\u2010Arnau A","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"e_1_2_19_88_1","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta\u2010analysis","volume":"175","author":"Guill\u00e9n\u2010Aguinaga S","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"e_1_2_19_89_1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4168\/aair.2023.15.4.496","article-title":"Efficacy of second\u2010line treatments in chronic urticaria refractory to standard dose antihistamines","volume":"15","author":"Kim MA","year":"2023","journal-title":"Allergy, Asthma Immunol Res"},{"issue":"7","key":"e_1_2_19_90_1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2340\/00015555-2941","article-title":"Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment","volume":"98","author":"Curto\u2010Barredo L","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"e_1_2_19_91_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14656566.2024.2345731","article-title":"An update on the use of antihistamines in managing chronic urticaria","volume":"25","author":"Xiang YK","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"e_1_2_19_92_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JAA.S14520","article-title":"Update on optimal use of omalizumab in management of asthma","volume":"4","author":"Pelaia G","year":"2011","journal-title":"J Asthma Allergy"},{"issue":"1","key":"e_1_2_19_93_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan A","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"e_1_2_19_94_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer M","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_2_19_95_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of Omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo\u2010controlled study","volume":"135","author":"Saini SS","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"6","key":"e_1_2_19_96_1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta\u2010analysis of randomized clinical trials","volume":"137","author":"Zhao ZT","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"e_1_2_19_97_1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.anai.2016.06.024","article-title":"Angioedema in the omalizumab chronic idiopathic\/spontaneous urticaria pivotal studies","volume":"117","author":"Zazzali JL","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"e_1_2_19_98_1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/all.12870","article-title":"Effect of omalizumab on angioedema in H1 \u2010antihistamine\u2010resistant chronic spontaneous urticaria patients: results from X\u2010ACT, a randomized controlled trial","volume":"71","author":"Staubach P","year":"2016","journal-title":"Allergy"},{"issue":"6","key":"e_1_2_19_99_1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.14075","article-title":"Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic\/spontaneous urticaria: analyses according to the presence or absence of angioedema","volume":"31","author":"Maurer M","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_2_19_100_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2017.10.010","article-title":"Omalizumab response in patients with chronic idiopathic urticaria: insights from the XTEND\u2010CIU study","volume":"78","author":"Casale TB","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"e_1_2_19_101_1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jamadermatol.2024.2056","article-title":"Multinational drug survival study of Omalizumab in patients with chronic urticaria and potential predictors for discontinuation","volume":"160","author":"Soegiharto R","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"e_1_2_19_102_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cea.70067","article-title":"Spectrum and impact of reported side effects of Omalizumab in patients with chronic urticaria: a long\u2010term multicentre real\u2010world study","volume":"55","author":"Soegiharto R","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"e_1_2_19_103_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and harms of Omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta\u2010analysis of \u201creal\u2010world\u201d evidence","volume":"155","author":"Tharp MD","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"18","key":"e_1_2_19_104_1","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.3390\/jcm13185610","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria in adults and adolescents: an eight\u2010year real\u2010life experience","volume":"13","author":"Calzari P","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"e_1_2_19_105_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.14540","article-title":"Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients","volume":"175","author":"Ghazanfar MN","year":"2016","journal-title":"Br J Dermatol"},{"issue":"9","key":"e_1_2_19_106_1","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/all.16256","article-title":"Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: a prospective multicentric observational study","volume":"79","author":"Pierrard G","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"e_1_2_19_107_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/aei.v53i2.1207","article-title":"Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria","volume":"53","author":"Akku\u015f FA","year":"2025","journal-title":"Allergol Immunopathol"},{"issue":"4","key":"e_1_2_19_108_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15586\/aei.v53i4.1443","article-title":"Biomarkers of response to omalizumab in patients with chronic spontaneous urticaria","volume":"53","author":"Akta\u015f \u00d6\u00d6","year":"2025","journal-title":"Allergol Immunopathol"},{"issue":"4","key":"e_1_2_19_109_1","first-page":"474","article-title":"Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response","volume":"121","author":"Nettis E","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"e_1_2_19_110_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacig.2024.100245","article-title":"Predicting responses to omalizumab in antihistamine\u2010refractory chronic urticaria: a real\u2010world longitudinal study","volume":"3","author":"Lee HY","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"5","key":"e_1_2_19_111_1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jaip.2019.01.026","article-title":"Relevance of the basophil high\u2010affinity IgE receptor in chronic urticaria: clinical experience from a tertiary care institution","volume":"7","author":"Deza G","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"e_1_2_19_112_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/cea.14462","article-title":"Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria","volume":"54","author":"Zubiaga\u2010Fernandez L","year":"2024","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"e_1_2_19_113_1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jaip.2018.02.024","article-title":"Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria","volume":"6","author":"Deza G","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"e_1_2_19_114_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.18176\/jiaci.0323","article-title":"Therapeutic strategy according to differences in response to Omalizumab in patients with chronic spontaneous urticaria","volume":"29","author":"Gim\u00e9nez Arnau AM","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"2","key":"e_1_2_19_115_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy J","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"e_1_2_19_116_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb H","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"e_1_2_19_117_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY\u2010CSU CUPID): two randomized, double\u2010blind, placebo\u2010controlled, phase 3 trials","volume":"154","author":"Maurer M","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_19_118_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2025.6023","article-title":"Dupilumab in patients with chronic spontaneous urticaria: phase 3 LIBERTY\u2010CSU CUPID randomized clinical trials","volume":"4","author":"Casale TB","year":"2026","journal-title":"JAMA Dermatol"},{"issue":"9","key":"e_1_2_19_119_1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","article-title":"Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels","volume":"14","author":"Maurer M","year":"2024","journal-title":"Dermatol Ther"},{"issue":"10","key":"e_1_2_19_120_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz M","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_2_19_121_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52\u2009weeks","volume":"153","author":"Jain V","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"e_1_2_19_122_1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer M","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"e_1_2_19_123_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-8411(88)90045-5","article-title":"Cyclosporine a and the regulation of autoimmune disease","volume":"1","author":"Lafferty KJ","year":"1988","journal-title":"J Autoimmun"},{"issue":"2","key":"e_1_2_19_124_1","doi-asserted-by":"crossref","first-page":"C250","DOI":"10.1007\/BF01997343","article-title":"Cyclosporin a inhibits histamine release from human peripheral basophils and human skin mast cells","volume":"36","author":"Amon EU","year":"1992","journal-title":"Agents Actions"},{"issue":"5","key":"e_1_2_19_125_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1346-8138.2008.00466.x","article-title":"Low\u2010dose and short\u2010term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation","volume":"35","author":"Serhat Inaloz H","year":"2008","journal-title":"J Dermatol"},{"issue":"2","key":"e_1_2_19_126_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double\u2010blind study of cyclosporin in chronic \u201cidiopathic\u201d urticaria","volume":"143","author":"Grattan CE","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"e_1_2_19_127_1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta\u2010analysis and systematic review","volume":"6","author":"Kulthanan K","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"e_1_2_19_128_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaip.2014.04.011","article-title":"Treatment of chronic urticaria in children with antihistamines and cyclosporine","volume":"2","author":"Neverman L","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"e_1_2_19_129_1","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1111\/jdv.18107","article-title":"Short courses of ciclosporin can induce long remissions in chronic spontaneous urticaria","volume":"36","author":"Alves F","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_2_19_130_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","article-title":"Cyclosporine in chronic idiopathic urticaria: a double\u2010blind, randomized, placebo\u2010controlled trial","volume":"55","author":"Vena GA","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"e_1_2_19_131_1","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jaip.2022.09.038","article-title":"Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring","volume":"10","author":"Kocaturk E","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"e_1_2_19_132_1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4168\/aair.2019.11.5.736","article-title":"Factors predicting the response to Cyclosporin treatment in patients with chronic spontaneous urticaria: a systematic review","volume":"11","author":"Kulthanan K","year":"2019","journal-title":"Allergy, Asthma Immunol Res"},{"issue":"1","key":"e_1_2_19_133_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjd.17005","article-title":"IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria","volume":"180","author":"Santiago L","year":"2019","journal-title":"Br J Dermatol"},{"issue":"7","key":"e_1_2_19_134_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","article-title":"Rilzabrutinib in antihistamine\u2010refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial","volume":"161","author":"Gim\u00e9nez\u2010Arnau A","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"6","key":"e_1_2_19_135_1","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti\u2010KIT Barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer M","year":"2025","journal-title":"Allergy"},{"key":"e_1_2_19_136_1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.anai.2025.08.040","article-title":"Povorcitinib demonstrates rapid improvement in hives and itch in patients with chronic spontaneous urticaria (CSU)","volume":"135","author":"Soong W","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"e_1_2_19_137_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.891","article-title":"Efficacy and safety of TLL\u2010018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamine: results from a phase Ib study","volume":"153","author":"Lu Q","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_19_138_1","doi-asserted-by":"crossref","unstructured":"KolkhirP SalamehP ZajacM Kasperska\u2010ZajacA Gim\u00e9nez\u2010ArnauA PuertolasM et\u00a0al.Unmet needs in treatment escalation for chronic spontaneous urticaria: findings from the CURE registry.Allergy2026.","DOI":"10.1111\/all.70199"},{"issue":"1","key":"e_1_2_19_139_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/ejd.2024.4600","article-title":"Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review","volume":"34","author":"Gimenez\u2010Arnau AM","year":"2024","journal-title":"Eur J Dermatol"},{"issue":"9","key":"e_1_2_19_140_1","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/all.16243","article-title":"Disease modification in chronic spontaneous urticaria","volume":"79","author":"Maurer M","year":"2024","journal-title":"Allergy"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70637","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70637","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:45:21Z","timestamp":1788936321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":139,"alternative-id":["10.1111\/jdv.70637"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70637","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"2026-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70637"}}